Clinical and laboratory factors associated with wound healing in patients with pyoderma gangrenosum: a retrospective study.


Journal

Wounds : a compendium of clinical research and practice
ISSN: 1943-2704
Titre abrégé: Wounds
Pays: United States
ID NLM: 9010276

Informations de publication

Date de publication:
06 2022
Historique:
pubmed: 30 6 2022
medline: 15 7 2022
entrez: 29 6 2022
Statut: ppublish

Résumé

Pyoderma gangrenosum (PG) is a rare, chronic, inflammatory, and ulcerative condition that often affects the lower extremities. Laboratory markers such as neutrophil-to-lymphocyte ratio, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) level may have prognostic utility in the management of ulcerative or inflammatory conditions. This exploratory analysis investigated the relationship between readily available clinical factors and target ulcer healing within 6 months from the first visit. Two logistic regression models were fit-one focused on ESR as a primary predictor adjusted for age and hemoglobin level, and the other focused on CRP level adjusted for body mass index (BMI) and smoking history. The odds of wound healing at 6 months for patients with abnormal CRP was 0.19 times the odds of healing (95% CI, 0.03-0.77) for those with normal CRP (<10 mg/L), after accounting for BMI and smoking. Similarly, after accounting for age and hemoglobin, those with high ESR experienced 2.81 times the odds of healing (95% CI, 0.69-14.58) at 6 months compared with patients with normal ESR. After adjustment, an increased CRP level was associated with lower odds of healing; however, further research is warranted to investigate its prognostic utility. The relationship between ESR and odds of healing should be interpreted with caution because the wide 95% CI for the adjusted odds ratio reflects marked uncertainty in the estimate. This research brief may inform investigations into inflammatory markers as possible prognostic markers for wound healing in patients with PG.

Identifiants

pubmed: 35767845
pii: WNDS20220415-1
pii:
doi:

Substances chimiques

Biomarkers 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

178-184

Auteurs

Stephen J Malachowski (SJ)

Virginia Commonwealth University Health System, Richmond, VA.

Emile Latour (E)

Oregon Health and Sciences University, Portland, OR; Knight Cancer Institute Biostatistics Shared Resource, Portland, OR.

Alex G Ortega-Loayza (AG)

Oregon Health and Sciences University, Portland, OR.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH